A prospective, randomized trial of complete avoidance of steroids in liver transplantation with follow-up of over 7 years.

PubWeight™: 0.81‹?›

🔗 View Article (PMC 3608983)

Published in HPB (Oxford) on September 28, 2012


Shawn J Pelletier1, Satish N Nadig, David D Lee, John B Ammori, Michael J Englesbe, Randall S Sung, John C Magee, Robert J Fontana, Jeffrey D Punch

Author Affiliations

1: Department of Surgery, University of Michigan, Ann Arbor, MI, USA.

Articles citing this

Towards Steroid-Free Immunosuppression after Liver Transplantation. Gut Liver (2016) 0.75

Articles cited by this


A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49

Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation (2004) 1.49

Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study. J Hepatol (2006) 1.23

Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg (1999) 1.17

Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology (1995) 1.16

Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl (2008) 1.10

Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation (2003) 1.07

Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. Liver Transpl (2005) 0.99

Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. Transplantation (1997) 0.99

Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transaminase levels versus necroinflammatory activity. Liver Transpl (2000) 0.96

Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes. Transpl Int (2009) 0.95

Steroid withdrawal at day 14 after liver transplantation: a double-blind, placebo-controlled study. Liver Transpl (2004) 0.93

Corticosteroid withdrawal after liver transplantation. Surgery (1995) 0.89

A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C. Transpl Int (2005) 0.89

Steroid-free immunosuppression during and after liver transplantation--a 3-yr follow-up report. Clin Transplant (2003) 0.86

Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up. Liver Transpl (2003) 0.85

The role of immunosuppression in recurrence of hepatitis C. Liver Transpl (2003) 0.84

Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transpl (2001) 0.82

Daclizumab induction and maintenance steroid-free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts. Transpl Int (2006) 0.82

Safety and efficacy of steroid-free immunosuppression with tacrolimus and daclizumab in liver transplant recipients: 6-year follow-up in a single center. Transplant Proc (2009) 0.82

Early steroid withdrawal in liver transplantation is safe and beneficial. Liver Transpl Surg (1999) 0.81

A "steroid-free" tacrolimus and low-dose mycophenolate mofetil primary immunosuppression does not prevent early acute rejection after liver transplantation. Transplant Proc (2005) 0.81

A pilot study on the safety and effectiveness of immunosuppression without prednisone after liver transplantation. Transplantation (1999) 0.81

A Randomized Multicenter Study Comparing a Tacrolimus-Based Protocol with and without Steroids in HCV-Positive Liver Allograft Recipients. J Transplant (2012) 0.80

Early cyclosporine monotherapy in liver transplantation: a 5-year follow-up of a prospective, randomized trial. Hepatology (1998) 0.80

First results from a prospective randomized trial comparing steroid-free induction therapy with tacrolimus and MMF versus tacrolimus and steroids in patients after liver transplantation for HCV. Transplant Proc (2002) 0.80

Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study. Transplant Proc (2005) 0.80

Retrospective analysis of 30 patients who underwent liver transplantation without use of steroids. Transplant Proc (1999) 0.79

Steroid withdrawal is safe and beneficial in stable cyclosporine-treated liver transplant patients. J Hepatol (1998) 0.79

Avoiding steroids in solid organ transplantation. Transpl Int (2003) 0.77

Withdrawal of immunosuppression in liver allograft recipients. Liver Transpl Surg (1998) 0.77

Steroid sparing protocols following nonrenal transplants; the evidence is not there. A systematic review and meta-analysis. Transpl Int (2011) 0.77

Maintenance immunosuppression using cyclosporine monotherapy in adult orthotopic liver transplant recipients. Transplant Proc (1996) 0.77

Articles by these authors

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40

Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med (2002) 11.38

Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology (2005) 10.66

Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45

A comprehensive risk quantification score for deceased donor kidneys: the kidney donor risk index. Transplantation (2009) 4.45

Predictors of postoperative acute renal failure after noncardiac surgery in patients with previously normal renal function. Anesthesiology (2007) 3.96

Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology (2005) 3.95

Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology (2009) 3.88

Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology (2006) 3.85

Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol (2005) 3.18

Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology (2008) 3.04

NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology (2002) 2.96

Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96

Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology (2011) 2.64

Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl (2005) 2.63

Endoscopic Transpapillary Gallbladder Stent Placement Is Safe and Effective in High-Risk Patients Without Cirrhosis. Dig Dis Sci (2014) 2.62

Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev (2012) 2.57

The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc (2006) 2.43

Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology (2010) 2.30

Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25

Gene expression signature for biliary atresia and a role for interleukin-8 in pathogenesis of experimental disease. Hepatology (2014) 2.20

Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med (2007) 2.17

Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology (2003) 2.05

Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol (2005) 2.04

12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int (2007) 2.03

Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01

Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology (2011) 1.98

Searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury. Am J Gastroenterol (2007) 1.98

Baseline Analysis of a Young α-1-Antitrypsin Deficiency Liver Disease Cohort Reveals Frequent Portal Hypertension. J Pediatr Gastroenterol Nutr (2015) 1.98

Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology (2005) 1.97

Biliary atresia: clinical profiles, risk factors, and outcomes of 755 patients listed for liver transplantation. J Pediatr (2005) 1.97

Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin Infect Dis (2005) 1.93

Association of center volume with outcome after liver and kidney transplantation. Am J Transplant (2004) 1.92

Association between sarcopenia and the risk of serious infection among adults undergoing liver transplantation. Liver Transpl (2013) 1.88

Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes. Hepatology (2006) 1.83

Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83

Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81

Seasonal variation in surgical outcomes as measured by the American College of Surgeons-National Surgical Quality Improvement Program (ACS-NSQIP). Ann Surg (2007) 1.81

Accelerating the pace of surgical quality improvement: the power of hospital collaboration. Arch Surg (2010) 1.80

Extrahepatic anomalies in infants with biliary atresia: results of a large prospective North American multicenter study. Hepatology (2013) 1.80

Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology (2006) 1.73

Surgical site infection and analytic morphometric assessment of body composition in patients undergoing midline laparotomy. J Am Coll Surg (2011) 1.73

Preoperative and intraoperative predictors of cardiac adverse events after general, vascular, and urological surgery. Anesthesiology (2009) 1.72

DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol (2008) 1.71

Effect of body mass index on the survival benefit of liver transplantation. Liver Transpl (2007) 1.69

Growth failure and outcomes in infants with biliary atresia: a report from the Biliary Atresia Research Consortium. Hepatology (2007) 1.68

Donation after cardiac death as a strategy to increase deceased donor liver availability. Ann Surg (2006) 1.66

Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol (2011) 1.65

Incremental costs of post-liver transplantation complications. J Am Coll Surg (2007) 1.63

Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl (2007) 1.61

Glycemic control promotes pancreatic beta-cell regeneration in streptozotocin-induced diabetic mice. PLoS One (2010) 1.58

Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol (2011) 1.57

Surgical site infection prevention: the importance of operative duration and blood transfusion--results of the first American College of Surgeons-National Surgical Quality Improvement Program Best Practices Initiative. J Am Coll Surg (2008) 1.56

Ex vivo-expanded human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model. Transplantation (2010) 1.55

Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Liver Transpl (2006) 1.55

Patient knowledge about disease self-management in cirrhosis. Am J Gastroenterol (2013) 1.55

Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology (2008) 1.53

Patients' perspectives of care and surgical outcomes in Michigan: an analysis using the CAHPS hospital survey. Ann Surg (2014) 1.52

Interaction between donor and recipient age in determining the risk of chronic renal allograft failure. J Am Geriatr Soc (2002) 1.49

Renal outcomes after liver transplantation in the model for end-stage liver disease era. Liver Transpl (2009) 1.49

Hepatitis C is a risk factor for death after liver retransplantation. Liver Transpl (2005) 1.48

The Michigan Surgical Quality Collaborative: a legacy of Shukri Khuri. Am J Surg (2009) 1.48

Financial implications of surgical complications in pediatric liver transplantation. Pediatr Transplant (2008) 1.48

There is plenty for everyone: transection of the infracardiac inferior vena cava during organ recovery. Liver Transpl (2012) 1.48

Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl (2005) 1.47

Frailty, core muscle size, and mortality in patients undergoing open abdominal aortic aneurysm repair. J Vasc Surg (2011) 1.47

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology (2009) 1.46

Ex vivo ureteroscopic treatment of calculi in donor kidneys at renal transplantation. J Urol (2004) 1.46

A Reassessment of the Survival Advantage of Simultaneous Kidney-Pancreas Versus Kidney-Alone Transplantation. Transplantation (2015) 1.44

Is routine ureteral stenting cost-effective in renal transplantation? J Urol (2007) 1.41

Transfusions in surgical patients. J Am Coll Surg (2005) 1.40

Transpapillary Gallbladder Stents Can Stabilize or Improve Decompensated Cirrhosis in Patients Awaiting Liver Transplantation. J Clin Gastroenterol (2015) 1.39

Failure to Rescue as a Quality Improvement Approach in Transplantation: A First Effort to Evaluate This Tool in Pediatric Liver Transplantation. Transplantation (2016) 1.39

Portal vein thrombosis and survival in patients with cirrhosis. Liver Transpl (2010) 1.38

Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol (2006) 1.38

Current status of kidney and pancreas transplantation in the United States, 1994-2003. Am J Transplant (2005) 1.37

A comparison of in-hospital mortality risk conferred by high hospital occupancy, differences in nurse staffing levels, weekend admission, and seasonal influenza. Med Care (2010) 1.36

Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology (2015) 1.36

Dermatofibrosarcoma protuberans: how wide should we resect? Ann Surg Oncol (2010) 1.35

Obesity, surgical site infection, and outcome following renal transplantation. Ann Surg (2009) 1.34

Adherence and health-related quality of life in adolescent liver transplant recipients. Pediatr Transplant (2008) 1.32

An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. Liver Transpl (2009) 1.31

Biliary complications following liver transplantation in the model for end-stage liver disease era: effect of donor, recipient, and technical factors. Liver Transpl (2008) 1.30

Frailty and delayed graft function in kidney transplant recipients. Arch Surg (2012) 1.30

Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry. Liver Int (2007) 1.30

The anatomic pattern of biliary atresia identified at time of Kasai hepatoportoenterostomy and early postoperative clearance of jaundice are significant predictors of transplant-free survival. Ann Surg (2011) 1.29

Measurement of foot traffic in the operating room: implications for infection control. Am J Med Qual (2009) 1.26